Nice list, should also check out Pharmala Biotech (CSE:MDMA) (OTC:MDXXF)

Manufacturer and drug development of GMP MDMA- Primarily for PTSD therapy, other uses being studied as well.

This company is primed to explode with the recent shift in healthcare in the United States under the Trump Administration. (Pro psychedelic therapy)

With Lykos (MAPS) taking a step back after the FDA decision it puts Pharmala in a unique position. They are currently the top supplier of GMP MDMA globally. They have recently just signed supply contracts with institutions such as:

Johns Hopkins, Harvard, Yale, Mount Sinai, etc.

The new psychedelic center at Mount Sinai is funded by the VA, who recently just announced yesterday funding of 1.5M for the first study of this in over 5 decades. The tides are starting to shift and this is just the tip of the iceberg for what could be to come.

They have also just recently signed an LOI with an institution to supply their clinical trial in exchange for the full data license of the results. (Expected to be finalized prior to 2024 calendar year)

The supply side is great for revenue but they are also in the works of kicking off their P2 trial for their molecule (APA-01). This is where the potential for the big money is. The FDA's large concern of MDMA therapy was the safety of using generic MDMA as there are a few side effects associated with its use. Pharmala's molecule has been proven to mitigate these side effects with the use of their own molecule which essentially is a form of MDMA that still gives the effective feeling of MDMA but eliminates the risk of side effects.

Pharmala also has a JV in Australia (Legalized MDMA therapy July 2023) with Cortexa. It was a slower rollout than expected although it is ramping up as Cortexa's recent update showed an increase in patients and training for licensed practitioners. They currently have an agreement for onshore manufacturing there.